Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen.
D000818:Animals; D001327:Autoimmune Diseases / Q000209:etiology*; D002272:Carcinoembryonic Antigen / Q000235:genetics / Q000276:immunology*; D003092:Colitis / Q000209:etiology*; D017491:Genes, APC; D016219:Immunotherapy, Adoptive / Q000009:adverse effects; D053645:Interleukin-2 Receptor alpha Subunit / Q000037:antagonists & inhibitors / Q000502:physiology; D007414:Intestinal Neoplasms / Q000276:immunology / Q000628:therapy*; D051379:Mice; D008822:Mice, Transgenic; D013601:T-Lymphocytes / Q000276:immunology*; D019444:Vaccines, DNA / Q000276:immunology; D014916:Whole-Body Irradiation
D002272:Carcinoembryonic Antigen; D053645:Interleukin-2 Receptor alpha Subunit; D019444:Vaccines, DNA